Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

56%

5 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

3(37.5%)

Phase 3

2(25.0%)

N/A

1(12.5%)

Phase 1

1(12.5%)

Phase 2

1(12.5%)

8Total

Phase 4(3)

Phase 3(2)

N/A(1)

Phase 1(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05533164Phase 3Active Not Recruiting

Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse

Role: collaborator

NCT05533125Phase 3Completed

Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed

Role: collaborator

NCT04673825Not ApplicableCompleted

Monitoring Spondyloarthritis With SpA-Net

Role: collaborator

NCT05251870Phase 1Unknown

Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis

Role: collaborator

NCT02996409Phase 4Completed

High-Volume Image-Guided Injection in Chronic Midportion Achilles Tendinopathy

Role: collaborator

NCT00128895Phase 4Terminated

Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis

Role: collaborator

NCT01345071Unknown

Preconceptional Counselling in Active Rheumatoid Arthritis

Role: collaborator

NCT01287715Phase 4Unknown

Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis

Role: collaborator

NCT00391924Phase 2Completed

Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome

Role: collaborator

All 9 trials loaded